FY2023 EPS Estimates for Zentalis Pharmaceuticals, Inc. Raised by Analyst (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at Leerink Partnrs upped their FY2023 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a research report issued on Tuesday, November 7th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($4.63) per share for the year, up from their prior forecast of ($5.39). Leerink Partnrs currently has a “Market Perform” rating on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($4.79) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2023 earnings at ($1.01) EPS, FY2024 earnings at ($4.51) EPS, FY2025 earnings at ($4.54) EPS and FY2026 earnings at ($3.83) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.13. During the same period in the previous year, the firm earned ($0.96) EPS.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus decreased their price target on Zentalis Pharmaceuticals from $44.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday. Wells Fargo & Company decreased their price target on Zentalis Pharmaceuticals from $51.00 to $50.00 and set an “overweight” rating for the company in a research note on Thursday, August 10th. Wedbush cut Zentalis Pharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $38.00 to $12.00 in a research note on Wednesday. HC Wainwright decreased their price target on Zentalis Pharmaceuticals from $55.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, SVB Leerink cut Zentalis Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $15.00 price target for the company. in a research note on Tuesday. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.70.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $9.97 on Thursday. The stock has a market capitalization of $705.54 million, a P/E ratio of -2.15 and a beta of 1.90. Zentalis Pharmaceuticals has a 1-year low of $9.56 and a 1-year high of $31.46. The business has a fifty day moving average price of $19.64 and a 200 day moving average price of $23.84.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of ZNTL. Matrix Capital Management Company LP grew its holdings in Zentalis Pharmaceuticals by 51.7% in the second quarter. Matrix Capital Management Company LP now owns 13,959,973 shares of the company’s stock valued at $393,811,000 after purchasing an additional 4,760,000 shares during the period. Eventide Asset Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 113.1% in the second quarter. Eventide Asset Management LLC now owns 6,877,803 shares of the company’s stock valued at $194,023,000 after acquiring an additional 3,650,803 shares in the last quarter. Cormorant Asset Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $30,890,000. State Street Corp lifted its position in shares of Zentalis Pharmaceuticals by 50.0% in the second quarter. State Street Corp now owns 3,119,734 shares of the company’s stock valued at $87,665,000 after acquiring an additional 1,039,294 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Zentalis Pharmaceuticals by 12.7% in the first quarter. FMR LLC now owns 8,912,751 shares of the company’s stock valued at $153,299,000 after acquiring an additional 1,003,575 shares in the last quarter.

Insider Activity

In related news, CFO Melissa B. Epperly sold 5,482 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $19.50, for a total transaction of $106,899.00. Following the sale, the chief financial officer now directly owns 387,691 shares of the company’s stock, valued at $7,559,974.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Melissa B. Epperly sold 5,482 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $19.50, for a total transaction of $106,899.00. Following the sale, the chief financial officer now directly owns 387,691 shares of the company’s stock, valued at $7,559,974.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Carrie Brownstein sold 10,628 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $19.50, for a total value of $207,246.00. Following the sale, the insider now directly owns 105,685 shares in the company, valued at $2,060,857.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,110 shares of company stock valued at $439,395. Company insiders own 6.10% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.